Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that occupies a central regulatory position within pulmonary immune networks, integrating inflammatory signalling, redox control, and immune-stromal communication. Originally characterised as a pro-inflammatory mediator, MIF is now recognised to exert context-dependent functions ranging from protective host defence during acute infection to the promotion of chronic inflammation, fibrosis, and tumour progression. This review synthesises current evidence on the molecular biology and signalling mechanisms governing MIF activity in the lung, highlighting its role as a network hub coordinating CD74/CD44- and CXCR-mediated signalling, glucocorticoid antagonism, and redox imbalance. A systems biology perspective illustrates how genetic variability, environmental exposure, ageing, and metabolic stress reprogram MIF-centred immune circuits across pulmonary diseases. Integration of multi-omics and computational modelling identifies opportunities for selective modulation of MIF signalling. Disease-specific roles in pneumonia, COPD, fibrosis, and lung cancer are discussed, positioning MIF as a key immunoregulatory node for future therapeutic strategies.
Aygun et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: